TY - JOUR
T1 - Targeted therapy in lymphoma
AU - Johnston, Patrick B.
AU - Yuan, Ruirong
AU - Cavalli, Franco
AU - Witzig, Thomas E.
N1 - Funding Information:
The authors thank Scientific Connexions for literature searching, medical writing, and editing services funded by Novartis Pharmaceuticals.
PY - 2010
Y1 - 2010
N2 - Discovery of new treatments for lymphoma that prolong survival and are less toxic than currently available agents represents an urgent unmet need. We now have a better understanding of the molecular pathogenesis of lymphoma, such as aberrant signal transduction pathways, which have led to the discovery and development of targeted therapeutics. The ubiquitin-proteasome and the Akt/mammalian target of rapamycin (mTOR) pathways are examples of pathological mechanisms that are being targeted in drug development efforts. Bortezomib (a small molecule protease inhibitor) and the mTOR inhibitors temsirolimus, everolimus, and ridaforolimus are some of the targeted therapies currently being studied in the treatment of aggressive, relapsed/refractory lymphoma. This review will discuss the rationale for and summarize the reported findings of initial and ongoing investigations of mTOR inhibitors and other small molecule targeted therapies in the treatment of lymphoma.
AB - Discovery of new treatments for lymphoma that prolong survival and are less toxic than currently available agents represents an urgent unmet need. We now have a better understanding of the molecular pathogenesis of lymphoma, such as aberrant signal transduction pathways, which have led to the discovery and development of targeted therapeutics. The ubiquitin-proteasome and the Akt/mammalian target of rapamycin (mTOR) pathways are examples of pathological mechanisms that are being targeted in drug development efforts. Bortezomib (a small molecule protease inhibitor) and the mTOR inhibitors temsirolimus, everolimus, and ridaforolimus are some of the targeted therapies currently being studied in the treatment of aggressive, relapsed/refractory lymphoma. This review will discuss the rationale for and summarize the reported findings of initial and ongoing investigations of mTOR inhibitors and other small molecule targeted therapies in the treatment of lymphoma.
UR - http://www.scopus.com/inward/record.url?scp=78549233720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78549233720&partnerID=8YFLogxK
U2 - 10.1186/1756-8722-3-45
DO - 10.1186/1756-8722-3-45
M3 - Review article
C2 - 21092307
AN - SCOPUS:78549233720
SN - 1756-8722
VL - 3
JO - Journal of Hematology and Oncology
JF - Journal of Hematology and Oncology
M1 - 45
ER -